A small but rigorous clinical trial in Argentina has found that blood plasma from recovered Covid-19 patients can keep older adults from getting seriously sick with the coronavirus — if they get the therapy within days of the onset of the illness.

WASHINGTON — Federal officials and drugmakers, faced with a slower-than-expected rollout of the coronavirus vaccine, are racing to find ways to expand the supply, looking at lowering the required dosage and extracting more doses from the supplies they have.

Just weeks into the vaccine program, scientists at the National Institutes of Health and the drugmaker Moderna are analyzing data to see if they can double the supply of the company’s coronavirus vaccine by cutting doses in half. The study, though long planned, is increasingly urgent in the face of looming shortages as the country tries to fight off a surging pandemic.

The National Climate Assessment, America’s premier contribution to climate knowledge, stands out for many reasons: Hundreds of scientists across the federal government and academia join forces to compile the best insights available on climate change. The results, released just twice a decade or so, shape years of government decisions.